drugset / Trial / NCT05992311
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
Phase 1
Recruiting
80 enrolled
Baylor College of Medicine
Michael E. DeBakey VA Medical Center · collabTexas A&M University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2028-04
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Montelukast | Other / unclassified | 40 mg | Oral |